Investigation on pharmacological properties of hexadiphane, oxazepam hemisuccinate and of their combination.
D000818:Animals; D001381:Azepines / Q000494:pharmacology* / Q000627:therapeutic use; D001555:Benzene Derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004158:Diphenylacetic Acids / Q000494:pharmacology; D004357:Drug Synergism; D005260:Female; D005704:Gallbladder / Q000187:drug effects; D006168:Guinea Pigs; D006591:Hexobarbital / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D010076:Oxazepam / Q000494:pharmacology* / Q000627:therapeutic use; D010208:Papaverine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D010433:Pentylenetetrazole / Q000494:pharmacology; D010437:Peptic Ulcer / Q000188:drug therapy; D051381:Rats; D012640:Seizures / Q000188:drug therapy; D012890:Sleep / Q000187:drug effects
D001381:Azepines; D001555:Benzene Derivatives; D004158:Diphenylacetic Acids; D010276:Parasympatholytics; D008694:Methamphetamine; D010076:Oxazepam; D006591:Hexobarbital; D010208:Papaverine; D010433:Pentylenetetrazole